SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3i9g'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1GTN_B_TRPB81_0 (TRP RNA-BINDING ATTENUATION PROTEIN)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	4 / 8	SER H 24 ALA H 78 HIS H 32 ILE H 51	None	0.77A	1gtnA-3i9gH: undetectable 1gtnB-3i9gH: 1.3	1gtnA-3i9gH: 12.83 1gtnB-3i9gH: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TZ8_C_DESC129_1 (TRANSTHYRETIN)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	4 / 6	LEU H 124 ALA H 137 SER H 127 SER H 128	None	1.05A	1tz8C-3i9gH: undetectable 1tz8D-3i9gH: undetectable	1tz8C-3i9gH: 21.36 1tz8D-3i9gH: 21.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UTD_F_TRPF81_0 (TRANSCRIPTION ATTENUATION PROTEIN MTRB)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	4 / 8	ALA H 78 HIS H 32 ILE H 51 SER H 24	None	0.81A	1utdF-3i9gH: undetectable 1utdG-3i9gH: 1.5	1utdF-3i9gH: 12.83 1utdG-3i9gH: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UTD_J_TRPJ81_0 (TRANSCRIPTION ATTENUATION PROTEIN MTRB)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	4 / 8	ALA H 78 HIS H 32 ILE H 51 SER H 24	None	0.79A	1utdJ-3i9gH: undetectable 1utdK-3i9gH: 1.5	1utdJ-3i9gH: 12.83 1utdK-3i9gH: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	4qvnH-3i9gH: undetectable 4qvnI-3i9gH: undetectable	4qvnH-3i9gH: 20.55 4qvnI-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 10	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	4qvnV-3i9gH: undetectable 4qvnW-3i9gH: undetectable	4qvnV-3i9gH: 20.55 4qvnW-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvpH-3i9gH: undetectable 4qvpI-3i9gH: undetectable	4qvpH-3i9gH: 20.55 4qvpI-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvpV-3i9gH: undetectable 4qvpW-3i9gH: undetectable	4qvpV-3i9gH: 20.55 4qvpW-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.86A	4qvqH-3i9gH: undetectable 4qvqI-3i9gH: undetectable	4qvqH-3i9gH: 20.55 4qvqI-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.85A	4qvqV-3i9gH: undetectable 4qvqW-3i9gH: undetectable	4qvqV-3i9gH: 20.55 4qvqW-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVV_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.90A	4qvvH-3i9gH: undetectable	4qvvH-3i9gH: 20.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVV_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.89A	4qvvV-3i9gH: undetectable	4qvvV-3i9gH: 20.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVY_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qvyH-3i9gH: undetectable	4qvyH-3i9gH: 20.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVY_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qvyV-3i9gH: undetectable 4qvyW-3i9gH: undetectable	4qvyV-3i9gH: 20.55 4qvyW-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW0_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qw0H-3i9gH: undetectable 4qw0I-3i9gH: undetectable	4qw0H-3i9gH: 20.55 4qw0I-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW0_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qw0V-3i9gH: undetectable 4qw0W-3i9gH: undetectable	4qw0V-3i9gH: 20.55 4qw0W-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qw1H-3i9gH: undetectable 4qw1I-3i9gH: undetectable	4qw1H-3i9gH: 20.55 4qw1I-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	4qw1V-3i9gH: undetectable 4qw1W-3i9gH: undetectable	4qw1V-3i9gH: 20.55 4qw1W-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BXN_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.88A	5bxnH-3i9gH: undetectable 5bxnI-3i9gH: undetectable	5bxnH-3i9gH: 20.55 5bxnI-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CZ7_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	5cz7V-3i9gH: undetectable 5cz7W-3i9gH: undetectable	5cz7V-3i9gH: 20.55 5cz7W-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5D0X_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.87A	5d0xV-3i9gH: undetectable	5d0xV-3i9gH: 20.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L5F_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	5l5fH-3i9gH: undetectable 5l5fI-3i9gH: undetectable	5l5fH-3i9gH: 20.55 5l5fI-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L5F_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	5l5fV-3i9gH: undetectable 5l5fW-3i9gH: undetectable	5l5fV-3i9gH: 20.55 5l5fW-3i9gH: 22.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BPY_A_ACTA408_0 (THIOREDOXIN REDUCTASE)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	3 / 3	PRO H 185 SER H 187 SER H 188	None	0.58A	6bpyA-3i9gH: undetectable	6bpyA-3i9gH: 18.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6CJK_B_ACTB302_0 (IMMUNOGLOBULIN FAB HEAVY CHAIN)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	3 / 3	TYR H 59 GLY H 65 THR H 68	None	0.16A	6cjkB-3i9gH: 23.8	6cjkB-3i9gH: 54.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_H_BO2H301_0 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.99A	6hwdH-3i9gH: undetectable 6hwdI-3i9gH: undetectable	6hwdH-3i9gH: 18.71 6hwdI-3i9gH: 13.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_V_BO2V301_0 (PROTEASOME SUBUNIT BETA TYPE-2)	3i9g	SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN (Mus musculus)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.99A	6hwdV-3i9gH: undetectable	6hwdV-3i9gH: 18.71

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1GTN_B_TRPB81_0","TRP RNA-BINDING ATTENUATION PROTEIN","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",4,"SER H  24;ALA H  78;HIS H  32;ILE H  51","None","0.77A","1gtnA-3i9gH:undetectable;1gtnB-3i9gH:1.3","1gtnA-3i9gH:12.83;1gtnB-3i9gH:12.83"],["1TZ8_C_DESC129_1","TRANSTHYRETIN;TRANSTHYRETIN","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",4,"LEU H 124;ALA H 137;SER H 127;SER H 128","None","1.05A","1tz8C-3i9gH:undetectable;1tz8D-3i9gH:undetectable","1tz8C-3i9gH:21.36;1tz8D-3i9gH:21.36"],["1UTD_F_TRPF81_0","TRANSCRIPTION ATTENUATION PROTEIN MTRB","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",4,"ALA H  78;HIS H  32;ILE H  51;SER H  24","None","0.81A","1utdF-3i9gH:undetectable;1utdG-3i9gH:1.5","1utdF-3i9gH:12.83;1utdG-3i9gH:12.83"],["1UTD_J_TRPJ81_0","TRANSCRIPTION ATTENUATION PROTEIN MTRB","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",4,"ALA H  78;HIS H  32;ILE H  51;SER H  24","None","0.79A","1utdJ-3i9gH:undetectable;1utdK-3i9gH:1.5","1utdJ-3i9gH:12.83;1utdK-3i9gH:12.83"],["4QVN_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","4qvnH-3i9gH:undetectable;4qvnI-3i9gH:undetectable","4qvnH-3i9gH:20.55;4qvnI-3i9gH:22.86"],["4QVN_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","4qvnV-3i9gH:undetectable;4qvnW-3i9gH:undetectable","4qvnV-3i9gH:20.55;4qvnW-3i9gH:22.86"],["4QVP_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvpH-3i9gH:undetectable;4qvpI-3i9gH:undetectable","4qvpH-3i9gH:20.55;4qvpI-3i9gH:22.86"],["4QVP_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvpV-3i9gH:undetectable;4qvpW-3i9gH:undetectable","4qvpV-3i9gH:20.55;4qvpW-3i9gH:22.86"],["4QVQ_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.86A","4qvqH-3i9gH:undetectable;4qvqI-3i9gH:undetectable","4qvqH-3i9gH:20.55;4qvqI-3i9gH:22.86"],["4QVQ_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.85A","4qvqV-3i9gH:undetectable;4qvqW-3i9gH:undetectable","4qvqV-3i9gH:20.55;4qvqW-3i9gH:22.86"],["4QVV_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.90A","4qvvH-3i9gH:undetectable","4qvvH-3i9gH:20.55"],["4QVV_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.89A","4qvvV-3i9gH:undetectable","4qvvV-3i9gH:20.55"],["4QVY_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qvyH-3i9gH:undetectable","4qvyH-3i9gH:20.55"],["4QVY_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qvyV-3i9gH:undetectable;4qvyW-3i9gH:undetectable","4qvyV-3i9gH:20.55;4qvyW-3i9gH:22.86"],["4QW0_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qw0H-3i9gH:undetectable;4qw0I-3i9gH:undetectable","4qw0H-3i9gH:20.55;4qw0I-3i9gH:22.86"],["4QW0_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qw0V-3i9gH:undetectable;4qw0W-3i9gH:undetectable","4qw0V-3i9gH:20.55;4qw0W-3i9gH:22.86"],["4QW1_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qw1H-3i9gH:undetectable;4qw1I-3i9gH:undetectable","4qw1H-3i9gH:20.55;4qw1I-3i9gH:22.86"],["4QW1_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","4qw1V-3i9gH:undetectable;4qw1W-3i9gH:undetectable","4qw1V-3i9gH:20.55;4qw1W-3i9gH:22.86"],["5BXN_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.88A","5bxnH-3i9gH:undetectable;5bxnI-3i9gH:undetectable","5bxnH-3i9gH:20.55;5bxnI-3i9gH:22.86"],["5CZ7_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","5cz7V-3i9gH:undetectable;5cz7W-3i9gH:undetectable","5cz7V-3i9gH:20.55;5cz7W-3i9gH:22.86"],["5D0X_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.87A","5d0xV-3i9gH:undetectable","5d0xV-3i9gH:20.55"],["5L5F_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","5l5fH-3i9gH:undetectable;5l5fI-3i9gH:undetectable","5l5fH-3i9gH:20.55;5l5fI-3i9gH:22.86"],["5L5F_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","5l5fV-3i9gH:undetectable;5l5fW-3i9gH:undetectable","5l5fV-3i9gH:20.55;5l5fW-3i9gH:22.86"],["6BPY_A_ACTA408_0","THIOREDOXIN REDUCTASE","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",3,"PRO H 185;SER H 187;SER H 188","None","0.58A","6bpyA-3i9gH:undetectable","6bpyA-3i9gH:18.67"],["6CJK_B_ACTB302_0","IMMUNOGLOBULIN FAB HEAVY CHAIN","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",3,"TYR H  59;GLY H  65;THR H  68","None","0.16A","6cjkB-3i9gH:23.8","6cjkB-3i9gH:54.71"],["6HWD_H_BO2H301_0","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.99A","6hwdH-3i9gH:undetectable;6hwdI-3i9gH:undetectable","6hwdH-3i9gH:18.71;6hwdI-3i9gH:13.96"],["6HWD_V_BO2V301_0","PROTEASOME SUBUNIT BETA TYPE-2","3i9g","SONEPCIZUMAB ANTIBODY FAB FRAGMENT, HEAVY CHAIN","Mus musculus",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.99A","6hwdV-3i9gH:undetectable","6hwdV-3i9gH:18.71"]]